Skip to main navigation Skip to search Skip to main content

Patient-reported outcomes in the subpopulation of patients with mismatch repair-deficient/microsatellite instability-high primary advanced or recurrent endometrial cancer treated with dostarlimab plus chemotherapy compared with chemotherapy alone in the ENGOT-EN6-NSGO/GOG3031/RUBY trial

  • Giorgio Valabrega
  • , Matthew A. Powell
  • , Sakari Hietanen
  • , Eirwen M. Miller
  • , Zoltan Novak
  • , Robert Holloway
  • , Dominik Denschlag
  • , Tashanna Myers
  • , Anna M. Thijs
  • , Kathryn P. Pennington
  • , Lucy Gilbert
  • , Evelyn Fleming
  • , Oleksandr Zub
  • , Lisa M. Landrum
  • , Beyhan Ataseven
  • , Radhika Gogoi
  • , Iwona Podzielinski
  • , Noelle Cloven
  • , Bradley J. Monk
  • , Sudarshan Sharma
    • Thomas J. Herzog, Ashley Stuckey, Bhavana Pothuri, Angeles Alvarez Secord, Dana Chase, Veena Vincent, Oren Meyers, Jamie Garside, Mansoor Raza Mirza, Destin Black

Research output: Contribution to journal › Article › peer-review

5   Link opens in a new tab Scopus citations

Fingerprint

Dive into the research topics of 'Patient-reported outcomes in the subpopulation of patients with mismatch repair-deficient/microsatellite instability-high primary advanced or recurrent endometrial cancer treated with dostarlimab plus chemotherapy compared with chemotherapy alone in the ENGOT-EN6-NSGO/GOG3031/RUBY trial'. Together they form a unique fingerprint.
Sort by

Keyphrases

Medicine and Dentistry

Pharmacology, Toxicology and Pharmaceutical Science